PATENT CLAIM ANALYSIS

Application Number: 16119263
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2018-12
Patent Classification: ["514", "263220"]

Abstract:
The invention discloses compositions comprising BRaf inhibitors and uses thereof for treating and/or preventing by topical or systemic administration cutaneous conditions caused by treatment with EGFR inhibitors and/or PI3K inhibitors.

Claim (Index 20):
A method for screening out of a BRaf inhibitor population, suitable BRaf inhibitors as candidates for clinical development of drugs for treating and/or preventing cutaneous reaction caused by treatment with EGFR inhibitor and/or PI3K inhibitors, the method comprising:\n (i) providing a population of known or new BRaf inhibitors; (ii) measuring the activation of MAPK (ERK) by said BRaf inhibitors; and (iii) selecting the BRaf inhibitors with the highest paradoxical MAPK activation effect as candidates for clinical development.

Metadata:
- Claim Count in Document: 17.0
- Percentile: 96.0
- Lexical Diversity: 1.14815
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15002457', '12865620', '14147689', '14770994', '15105904']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7412529026375233
- 35 USC 102 Novelty (BERT): 0.529375127403531
- Combined Prediction Score: 0.720065125114124
- Mean Citation Score: 302.35572
- Max Citation Score: 316.7195700000001
- Similarity Product: 198.72385965169613

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test